The US Food and Drug Administration should take steps to discourage its medical product center directors from influencing votes at advisory committee meetings and overruling review staff on product applications, a coalition of patient and consumer groups said.
In a 12 July letter to FDA Commissioner Robert Califf, members of the Patient, Consumer and Public Health Coalition...





